AVJ16
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 with a good affinity of Kd of 1.4μM. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation[1].
Product Specifications
CAS Number
[2775241-92-2]
UNSPSC
12352005
Target
Apoptosis; Insulin Receptor
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/avj16.html
Concentration
10mM
Purity
99.60
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(N1CCN(CC1)C2=CC3=C(OCO3)C=C2)C4=CC=C(C=C4)CN5C(CO)=CC6=C5C=CC=C6
Molecular Formula
C28H27N3O4
Molecular Weight
469.53
References & Citations
[1]Singh A, et al. Development of a Novel IGF2BP1 Inhibitor as Metastasis-Specific Therapeutic Agent[J]. European Journal of Cancer, 2022, 174: S104-S105.|[2]Wallis N, et al. AVJ16 inhibits the RNA binding protein IGF2BP1 in lung adenocarcinomas and prevents tumor growth in mice[J]. bioRxiv, 2024: 2024.08. 15.608038.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
C2400-42C-ML490 100 µL
CD45RA (CD45 Antigen, B220, GP180, Leukocyte Common Antigen, LCA, L-CA, LY5, LY-5, Protein Tyrosine Phosphatase Receptor Type C Polypeptide, PTPRC, T200, T200 Glycoprotein) (MaxLight 490)
Ask
View Details 
475021 100 µL
AKR1C2 (Aldo-Keto Reductase Family 1 Member C2, Aldo-Keto Reductase Family 1, Member C2 (Dihydrodiol Dehydrogenase 2; Bile Acid Binding Protein; 3-Alpha Hydroxysteroid Dehydrogenase, Type III) )
Ask
View Details